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PROBLEM IDENTIFICATION AND DESCRIPTION OF 
NEED
The opioid crisis has warranted 
nationwide attention towards not only 
the current prescribing patterns of 
pain medications, but also towards 
rehabilitating affected members of 
the community. Current interventions 
include the use of suboxone 
(buprenorphine + naloxone) as well 
as Subutex (buprenorphine). 
As the implementation of partial 
opioid antagonists increase on a 
statewide level (1), investigating 
factors such as drivers of substance 
relapse are worth considering to 
further improve adherence to 
currently available treatment 
regimens. 
PROBLEM IDENTIFICATION AND DESCRIPTION OF 
NEED
As previously investigated by Kadam et.al., sociodemographic factors such as single 
status, unemployment, lower socioeconomic status, and criminal history drove relapse in 
individuals with alcohol or opioid dependence. For opioid dependence in particular, 
cravings and perceived criticism were also commonly cited as reasons to relapse. (2) 
Smyth et.al. noted a 91% reported relapse rate in a study of consecutive opioid 
dependent patients admitted to a residential addiction treatment facility. In these 
individuals, relapse was noted to have occurred within the first week in 59% of cases. (3)
PUBLIC HEALTH COST AND COST 
CONSIDERATIONS
•As mentioned by Florence et.al., the cost of the opioid crisis from a nationwide study 
in 2013 was estimated to be $78.5 billion with over a third of this amount due to 
increased healthcare and substance abuse treatment costs. (4) 
•Opioid partial antagonists such as Suboxone were leaders in both spending and 
utilization in the 2018 Vermont State Pharmacy Best Practices and Cost Control 
Report. Claims were noted to have increased by 8.3% with Suboxone utilization 
increasing by 10%. (1) 
•Through the opioid initiatives implemented by the State of Vermont, opioid utilization 
decreased by 30% with the number of individual opioid users down 36%. (5)
COMMUNITY PERSPECTIVE
“I think some of the common characteristics of patients that have relapsed are those patients who 
are not completely committed to their sobriety, they want to game the system (getting Suboxone 
but continuing to use illicit substances), they are not always truthful about what is going on in 
their lives or about what substances they used. They deny the use of any illicit substance despite 
the evidence of use in their urine screens. These patients are the more difficult patients to work 
with in an office setting. I don't think they realize that the only ones they are hurting are 
themselves and their families.” 
(Barbara Wynes, MAT RN Care Coordinator)
Stress has been a common additional theme amongst patients that tended to relapse, making it 
significantly more difficult for patients to adhere to treatment as well as refrain from substance 
usage. These stressors often include recent deaths, poverty, and unemployment. 
(Summary from interview of Chelsea Poland, MAT Care Coordinator)
INTERVENTION AND METHODOLOGY
This study took place in Swanton, VT, a small town in Franklin County, Vermont at a rural 
private family medicine practice. To determine general drivers of relapse in Northwest 
Vermont, a small survey was developed in coordination with MAT providers that resided within 
this practice. Surveys were provided to all patients in the clinic, however only those that 
checked suboxone usage were retained for analysis. This survey was designed for suboxone 
users as it was the most commonly prescribed medication within this target demographic. 45 
survey respondents along with their responses remained confidential and were not shown to 
providers to avoid identification of specific individuals through association. This survey ran for 
8 business days between the months of July and August 2019. Specific dates were 
intentionally excluded to avoid identification of respondents. 
Investigated variables were: duration of treatment, age, current employment status, history of 
relapse, reasons for relapse, difficult substances to avoid, and open-ended suggestions. Survey 
responses were then tallied and aggregated into appropriate visual formats in a handout 
format. This handout was presented to MAT providers to better provide targeted care to 
current and future individuals in a suboxone treatment program.
RESULTS/RESPONSES
▪Number of respondents: 45
▪Average length of maintenance treatment: 6.5 years
▪Age distribution: >50 y.o. (11%), <50 y.o. (89%)
▪Overall relapse rate: 53.3%
▪Most common reasons for relapsing: Cravings, Access to Substances, Stress
▪Most difficult substances to avoid during treatment: Prescription Opioids, 
Crack/Cocaine, Heroin
▪Most common community suggestion: Would like to be able to speak to someone 
unrelated to treatment team about my problems

































































































Difficult substances to avoid 
during treatment
*: stress, grief, life crisis, 




• The conclusions provided by this study serve to reinforce prior studies in regards to contributors to relapse. 
•As the reported relapse rate by the individuals in this study were lower then expected, it may suggest the interventions 
provided by the MAT coordinators were effective. 
•Continued effort and awareness of the specific struggles unique to this community will be essential towards adapting to 
changing substance use patterns over time, especially with the recent rise of stimulant use (crack/cocaine). These tracking 
forms provided valuable data regarding existing patterns as well as to how the patient population is evolving.
Limitations:
•As this study was performed in a rural community, the results may not translate into higher population areas and their greater 
inherent variability. 
•Another limitation is response bias due to stigmatization or misinterpretation of questions due to limited education. 
• Those in treatment for a longer duration may also exhibit different characteristics compared to those that paused treatment 
post- early relapse.
FUTURE INTERVENTIONS
•Future directions include investigating rates of relapse in relation to suboxone dosing 
and tapering. 
•As many individuals noted cravings and difficulty refraining from prescription opioid 
use as being the top contributors, it may be worth looking into the how tapers affect 
end-treatment relapse rates. 
•In many cases, tapering a patient off Suboxone continues to be a challenge and their 
responses are often unpredictable.
•Quote from anonymous respondent on feedback form:
• “The #1 concern I feel is the greatest threat is getting off suboxone. There don’t seem to be any other 
methods than taper. Most people can’t get rid of the last doses.”
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